Therapeutic antibody expression technology (Q33941400)

30 July 2017

Therapeutic antibody expression technology (English)

1 reference

30 July 2017

1 reference

Chadd HE

1

1 reference

PubMed ID

11287236

30 July 2017

Chamow SM

series ordinal

2

1 reference

30 July 2017

1 April 2001

1 reference

Current Opinion in Biotechnology

30 July 2017

1 reference

30 July 2017

12

1 reference

30 July 2017

2

1 reference

30 July 2017

188-194

1 reference

Transgenic mice as a source of fully human antibodies for the treatment of cancer

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Generation of recombinant antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Very high expression of an anti-carcinoembryonic antigen single chain Fv antibody fragment in the yeast Pichia pastoris

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Recent progress in biomolecular engineering

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

The structural requirements for complement activation by IgG: does it hinge on the hinge?

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Biology of Human Immunoglobulin G Fc Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

High cytoplasmic expression in E. coli, purification, and in vitro refolding of a single chain Fv antibody fragment against the hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Cloning and expression of single chain antibody fragments in Escherichia coli and Pichia pastoris.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Comparative sensitivity of immunoassays for haptens using monomeric and dimeric antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Expression of functional recombinant antibody molecules in insect cell expression systems

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Therapeutic antibody fragments with prolonged in vivo half-lives

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Fed-batch culture of recombinant NS0 myeloma cells with high monoclonal antibody production

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Transgenic milk as a method for the production of recombinant antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Foreign protein production in plant tissue cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Delivery of immunoprophylactics in transgenic plants: current status

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

Ten years of Orthoclone OKT3 (muromonab-CD3): a review

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2800%2900198-1

7 January 2021

10.1016/S0958-1669(00)00198-1

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

11287236